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Summary
The aberrant transcription factor EWS-FLI1 drives Ewing sarcoma yet its molecular function is 
incompletely understood. We find that EWS-FLI1 reprograms gene regulatory circuits in Ewing 
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sarcoma by directly inducing or repressing enhancers. At GGAA repeat elements, which lack 
evolutionary conservation and regulatory potential in other cell types, EWS-FLI1 multimers 
induce chromatin opening and create de novo enhancers that physically interact with target 
promoters. Conversely, EWS-FLI1 inactivates conserved enhancers containing canonical ETS 
motifs by displacing wild type ETS transcription factors. These divergent chromatin-remodeling 
patterns repress tumor suppressors and mesenchymal lineage regulators, while activating 
oncogenes and new potential therapeutic targets, such as the kinase VRK1. Our findings 
demonstrate how EWS-FLI1 establishes an oncogenic regulatory program governing both tumor 
survival and differentiation.
Introduction
Transcriptional regulators, including transcription factors, chromatin modifiers and histones, 
are key mediators of proliferation and differentiation in normal development and cancer. 
Such genes are frequent targets of genetic alterations in tumors and can be important 
contributors to transformation through the dysregulation of transcriptional programs (Baylin 
and Jones, 2011; Lee and Young, 2013). Pediatric tumors offer unique opportunities to study 
these events in relative isolation since they have stable genetic backgrounds and small 
numbers of genetic alterations that often involve transcriptional regulators (Kadoch and 
Crabtree, 2013; Roberts et al., 2000; Schwartzentruber et al., 2012). This is in sharp contrast 
to most tumors in adults where the genome-wide analysis of regulatory networks is 
complicated by many recurrent mutations and genomic instability.
Ewing sarcoma, the second most common bone malignancy in children and young adults, is 
a prototypical example of a pediatric tumor with a dominant genetic alteration in a 
transcriptional regulator. Ewing sarcoma is characterized by chromosomal translocations 
that generate fusions between the EWS gene and members of the ETS family of transcription 
factors, by far the most common being FLI1 (Delattre et al., 1992). The importance of the 
translocation is further supported by the fact that it occurs in the setting of one of the lowest 
mutation rates among all cancer types (Lawrence et al., 2013). The EWS-FLI1 oncogenic 
fusion protein not only constitutes a defining diagnostic feature of Ewing sarcoma but also 
underlies its pathogenesis. Indeed, several studies have shown EWS-FLI1 to be crucial for 
the growth and survival of Ewing sarcoma cells and sufficient for the transformation of 
primary mesenchymal stem cells (Riggi et al., 2005; Riggi et al., 2008), a putative cell of 
origin.
Gene expression studies have shown that the oncogenic properties of EWS-FLI1 are linked 
to a complex transcriptional program that involves both gene activation and repression 
(Riggi and Stamenkovic, 2007). The pathways implicated include known mediators of 
transformation as well as genes involved in cellular differentiation that point to the 
interruption of normal mesenchymal development. This is consistent with the proposed 
origin of Ewing sarcoma from mesenchymal stem cells (MSCs) and with experiments 
showing that EWS-FLI1 can transform these cells and prevent their differentiation into 
osteogenic and adipogenic fates (Torchia et al., 2003). EWS-FLI1 is thus capable of eliciting 
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profound changes in gene regulation and reprograms precursor cells to establish a distinct 
differentiation and oncogenic state.
The mechanisms by which EWS-FLI1 directly regulates target genes are less well 
understood. EWS-FLI1 binding sites have been previously described (Bilke et al., 2013; 
Gangwal et al., 2008; Guillon et al., 2009; Patel et al., 2012) but the direct chromatin 
remodeling events leading to gene activation and repression remain to be fully elucidated. 
Here we pursued the coordinated analysis of chromatin states at EWS-FLI1 binding sites in 
Ewing sarcoma primary tumors, cell lines and precursor pediatric mesenchymal stem cells to 
characterize the mechanisms by which EWS-FLI1 directly modulates critical transformation 
and differentiation pathways.
Results
EWS-FLI1 binds cis-regulatory elements shared by Ewing sarcoma cell lines and primary 
tumors
In order to map EWS-FLI1 and its associated chromatin states we first identified direct 
binding sites of endogenous EWS-FLI1 in two well-defined Ewing sarcoma cell lines, A673 
and SKNMC. This was achieved by chromatin immunoprecipitation and sequencing (ChIP-
seq) with an antibody directed against the C-terminal portion of FLI1 contained in EWS-
FLI1 (endogenous FLI1 is not expressed in either line). 1785 EWS-FLI1 peaks were present 
in both SKNMC and A673 cells at high significance (p-value < 10−5) and were defined as a 
core set of EWS-FLI1 binding sites for analysis (Fig. S1A and Table S1). 90% of these sites 
were located in intergenic and intronic regions (Fig. S1B), and 75% were found to overlap 
with a recent EWS-FLI1 profiling performed in A673 cells (Bilke et al., 2013). To relate 
these binding sites to cis-regulatory elements and epigenetic states, we mapped key histone 
modifications, including Histone H3 lysine 27 acetylation (H3K27ac), H3 lysine 4 mono-
methylation (H3K4me1), H3 lysine 4 tri-methylation (H3K4me3) and H3 lysine 27 tri-
methylation (H3K27me3). We found that the majority of EWS-FLI1 binding sites are 
enriched for H3K4me1, a ubiquitous marker of cis-regulatory elements (Fig. 1A, 87% of 
sites have strong signals in both cell lines). However, they display variable levels of 
H3K27ac, a more specific marker of enhancer activity (Fig. 1A, 78% of sites were positive 
in both cell lines with a large variation in signal intensity). In contrast, essentially all 
promoters bound by EWS-FLI1 carry H3K4me3, a mark of transcriptional initiation (Fig. 
1B, 99% of all bound promoters).
We also mapped these modifications in a set of primary Ewing sarcoma tumors and in 
MSCs. Chromatin patterns over EWS-FLI1 binding sites were highly concordant between 
Ewing sarcoma cell lines and the primary tumors (Fig. 1A, 86% of sites are concordant for 
H3K4me1 and 75% for H3K27ac), but distinct from those in mesenchymal stem cells, 
suggesting that the cell line models are representative of the native tumor environment at 
these sites (Fig. S1C). Genes proximal to EWS-FLI1 bound enhancers include known 
regulators with critical functions in Ewing sarcoma, such as CCND1 and NKX2-2, as well as 
many novel targets (Fig. 1D). Since EWS-FLI1 has been shown to have both positive and 
negative effects on gene expression (Riggi and Stamenkovic, 2007), we considered the 
possibility that EWS-FLI1 regulation might involve Polycomb-mediated repression. 
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However, we observed essentially no overlap between EWS-FLI1 binding sites and 
H3K27me3, a repressive modification deposited by Polycomb repressive complexes 
(Margueron and Reinberg, 2011), in either the cell lines or the primary tumors (Fig. 1C, Fig. 
S1D).
EWS-FLI1 bound distal regulatory elements are either directly activated or repressed by 
the fusion protein
To test the functional impact of EWS-FLI1 on enhancer activity directly, we depleted the 
fusion by shRNA and measured ensuing changes in chromatin state. We confirmed an 85% 
reduction in EWS-FLI1 protein levels and a marked decrease in EWS-FLI1 ChIP-seq 
signals at binding sites, thus validating the knock-down and the specificity of the ChIP-seq 
signal for EWS-FLI1 (Fig. S2A, ChIP-seq signals decreased more than 1.5 fold at 93% of 
our core set of 1785 EWS-FLI1 peaks). EWS-FLI1 depletion significantly altered global 
enhancer patterns in the tumor cell lines, such that they more closely resembled the non-
transformed MSCs (Fig. S2C). In particular,, loss of EWS-FLI1 elicited divergent responses 
at target sites, with some cis-regulatory elements displaying marked increases in H3K27ac 
levels and others displaying equally strong decreases in this marker for enhancer activity 
(Fig. 2A). Classification of binding sites by changes in H3K27ac levels revealed 1011 EWS-
FLI1-activated and 330 EWS-FLI1-repressed loci (fold-change >1.5; Fig. 2A). Chromatin 
state changes were evident at 48 hr, indicating that they represent rapid events, and became 
more pronounced by 96 hr. Results were also highly concordant between the two cell lines 
(Fig. S2B, correlation coefficients of 0.83 at 48 hr and 0.76 at 96 hr). We did not observe 
changes in H3K27me3 at either class of target elements, ruling out a role for Polycomb 
repressors in direct regulation of enhancers by EWS-FLI1 (Fig. S2D).
The rapid and robust changes in H3K27ac led us to hypothesize that they might reflect direct 
interactions between EWS-FLI1 and chromatin remodeling complexes. We focused initially 
on the acetyltransferase p300, a chromatin regulator implicated in enhancer activity (Visel et 
al., 2009) and previously shown to interact with EWS-FLI1 to mediate p53 acetylation and 
apoptosis in response to toxic stress (Ramakrishnan et al., 2004). We confirmed that EWS-
FLI1 binds p300 in SKNMC cells by co-immunoprecipitation (Fig. S2E). We then mapped 
p300 binding genome-wide before and after EWS-FLI1 knock-down in the Ewing sarcoma 
lines. We observed strong p300 signals in 75% of activated EWS-FLI1 binding sites and 
dynamic changes in p300 occupancy that were closely coordinated with decreases in 
H3K27ac in activated sites and increases in H3K27ac at repressed sites upon depletion of 
the translocation (Fig. 2A, correlation coefficient 0.75). This suggests that differential 
effects of EWS-FLI1 on p300 recruitment may underlie its divergent effects on enhancer 
activity (Fig. 2B, C).
The functional output of EWS-FLI1 binding is determined by the underlying DNA sequence
To investigate the mechanistic basis of the divergent effects of EWS-FLI1 on p300 
recruitment and enhancer activity, we examined the primary DNA sequence underlying the 
fusion protein binding sites. De novo motif analysis revealed that the activated and repressed 
binding sites have distinct sequence determinants. Cis-regulatory elements activated by 
EWS-FLI1 are strongly enriched for GGAA repeats, with 75% of activated sites containing 
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4 or more repeats. In contrast, repressed sites contain canonical non-repetitive ETS motifs in 
85% of cases (Fig. 2A, B, C). Other motifs were present at much lower significance (Fig. 
S2F). GGAA repeats have been previously implicated in Ewing sarcoma on the basis of 
their association with open chromatin and proximity to some activated genes (Gangwal et 
al., 2008; Guillon et al., 2009). In biochemical experiments EWS-FLI1 has been shown to 
bind these elements as homodimers at optimal lengths of 4 or more consecutive GGAA 
repeats (Gangwal et al., 2008; Guillon et al., 2009). Our results show that EWS-FLI1 
multimers at GGAA repeats promote the recruitment of p300 to these sites, leading to 
histone acetylation and an active enhancer state.
GGAA repeat enhancers appear unique to Ewing sarcoma
The strong association between the function of EWS-FLI1 and DNA sequence prompted us 
to investigate whether the two classes of EWS-FLI1 binding sites may have different 
regulatory activities in other cellular contexts. To this effect, we examined previously 
published DNAse I hypersensitivity data for 112 cell and tissue types (ENCODE, 2011; 
Thurman et al., 2012). With the exception of the SKNMC Ewing cell line, we did not 
identify any other cell type in which GGAA repeats activated by EWS-FLI1 show evidence 
of accessibility or activity (Fig. 3A). In contrast, sites repressed by EWS-FLI1 exhibit strong 
DNAse I signals in multiple cell types. We also examined evolutionary conservation at 
EWS-FLI1 binding sites to explore whether these elements might have selected functions in 
other cellular or developmental contexts. Remarkably, conservation of GGAA repeat sites 
and adjacent sequences is essentially indistinguishable from genomic background (Fig. 3B). 
In contrast, repressed target sites are highly conserved. Thus, while repressed target sites 
have characteristic features of enhancers, our analysis suggests that GGAA repeat activation 
may be specific to the setting of Ewing sarcoma.
To examine how EWS-FLI1 establishes tumor specific active enhancers, we turned to 
primary pediatric MSCs. In contrast to other cell types where expression of EWS-FLI1 leads 
to growth arrest and apoptosis, induction of the fusion in MSCs results in transformation and 
activation of a set of genes that closely recapitulate the Ewing sarcoma phenotype (Riggi et 
al., 2005; Riggi et al., 2010). We therefore infected MSCs with an EWS-FLI1 expression 
construct (Fig. S3A, S3B) and measured consequent changes in DNA accessibility and 
chromatin state (Fig. 3C, S3D). As in other cell types, activated EWS-FLI1 sites have a 
closed chromatin conformation in primary MSCs, as indicated by the absence of DNAse I 
hypersensitivity, H3K4me1 and H3K27ac signals (Fig. 3C, S3C) (ENCODE, 2011; 
Thurman et al., 2012). However, upon EWS-FLI1 induction, these sites switch to an open 
chromatin conformation, as indicated by ATAC-seq chromatin accessibility measurements 
(Fig. 3E and F, 77% of activated sites increase more than 1.5 fold). Moreover, EWS-FLI1 
induction causes significant increases in both H3K4me1 and H3K27ac at 78% of these sites, 
resulting in an active enhancer-like pattern analogous to their state in Ewing sarcoma cell 
lines and primary tissues (Fig. 3C, 3E and S3D).
Enhancer priming has been linked to MLL family protein complexes that catalyze H3K4 
methylation (Kaikkonen et al., 2013; Smith et al., 2011), leading us to hypothesize that 
EWS-FLI1 might recruit chromatin remodeling subunits in addition to p300. Consistent with 
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this possibility, we identified interactions between EWS-FLI1, and two components shared 
by all human MLL complexes, WDR5 and ASH2, by co-immunoprecipitation experiments 
(Fig. S3E and F). WDR5 occupancy at activated EWS-FLI1 sites in SKNMC and A673 
cells was also detected by ChIP-seq (Fig. 3D and S3G, 88% of activated sites). 
Accordingly, ChIP-seq profiling of MSCs before and after fusion gene induction 
demonstrated that EWS-FLI1 recruits WDR5 to activated enhancers (Fig. 3E, F, 63% of 
activated sites increase more than 1.5 fold). Finally, chromatin conformation analysis 
showed a direct physical interaction between the NKX2-2 promoter and the corresponding 
distal regulatory element in both SKNMC and A673 cells (Fig. 3G and S3H, respectively). 
A similar high-order chromatin organization was induced in mesenchymal stem cells by 
DNA looping upon expression of EWS-FLI1 (Fig 3H). EWS-FLI1 can thus act as a pioneer 
factor and generate active enhancers de novo in mesenchymal stem cells by increasing 
chromatin accessibility, directing the recruitment of histone methyltransferases and 
acetyltransferases and resulting in the establishment of long range regulatory interactions.
Given that our data point to a direct distal regulatory role for EWS-FLI1 bound GGAA 
repeats and that variations in repeat size have been proposed as a potential contributor to 
Ewing sarcoma susceptibility (Beck et al., 2012), we also considered whether EWS-FLI1 
bound repeat elements may exhibit length variability. Since Ewing sarcoma displays a ten-
fold higher incidence in European compared to African populations we matched EWS-FLI1 
bound GGAA repeats to recent data for variation in microsatellite repeat lengths (Genomes 
Project et al., 2012; Thomas F. Willems, 2014). 36 out of 244 sites for which variation data 
were available displayed statistically significant differences between these two groups (25 
were longer in Europeans, Table S2). Thus, EWS-FLI1 bound repeat sites display 
variability in length between populations and may provide insights into tumor susceptibility.
EWS-FLI1 directly represses targets by displacing wild type ETS factors from 
mesenchymal enhancers
We next considered the mechanism by which EWS-FLI1 binding at repressed target sites 
instead causes a reduction in p300 occupancy and H3K27ac levels. In contrast to activated 
sites, repressed sites occupy highly conserved genomic locations (Fig. 3B) and contain 
canonical ETS sequences recognized by a large family of transcriptional activators. 
Consistently, many of the sites correspond to enhancers that are active in multiple 
mesenchymal cell types, including primary MSCs, differentiated osteoblasts and skeletal 
muscle, but not in embryonic stem cells or neural progenitors (ENCODE, 2011) (Fig. 4A).
We hypothesized that wild type ETS activators might be displaced by EWS-FLI1 at these 
sites leading to a disruption of mesenchymal lineage enhancers, thus facilitating the 
interruption of mesenchymal differentiation characteristic of Ewing sarcoma. To test this 
hypothesis, we examined the influence of EWS-FLI1 binding on ETS factor occupancy. We 
focused on the ETS-related transcription factor ELF1, which has similar sequence 
preference to FLI1 and is expressed in A673 and SKNMC cells. We surveyed ELF1 binding 
in SKNMC cells by ChIP-seq before and after EWS-FLI1 knock-down (Fig. 4B and S4A). 
Depletion of the fusion protein led to a marked increase in ELF1 binding at a substantial 
subset of EWS-FLI1-repressed enhancers (Fig. 4B, C and S4B). We also examined a 
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second ETS factor, GABPA, and found that it also localizes to many EWS-FLI1 enhancers 
after depletion of the fusion protein (Fig. S4C and D). A combined analysis of ELF1 and 
GABPA occupancy changes shows that repressed sites may exhibit increases in either 
transcription factor separately or a gain of both ELF1 and GABPA together after EWS-FLI1 
knock-down (Fig. S4D and E). ETS factors such as ELF1 and GABPA are known to 
robustly recruit p300, while EWS-FLI1 lacks one of the two p300 binding domains 
contained in wild type FLI1 and thus has weak p300 recruitment when it does not bind as 
multimers (Hollenhorst et al., 2011). Thus, the restoration of wild type ETS factor binding 
likely explains the increased histone acetylation and enhancer activity observed at EWS-
FLI1 sites upon fusion protein depletion. Our findings suggest that EWS-FLI1 represses this 
subset of conserved enhancers directly by displacing more active wild type ETS family 
members from their native binding sites.
EWS-FLI1 mediated chromatin remodeling is associated with expression changes in target 
genes involved in tumor survival and differentiation pathways
Finally, we sought to address the impact of altered cis-regulatory element activity on the 
transcriptional landscape of Ewing sarcoma. We performed RNA sequencing (RNA-seq) in 
the Ewing sarcoma lines before and after EWS-FLI1 knock-down. By mapping EWS-FLI1 
distal elements to the nearest expressed genes, we observed a strong relationship between 
changes in enhancer activity and changes in proximal gene expression (p < 10−10). We 
confirmed a subset of regulated gene targets by qRT-PCR (Fig. S5A). Activated targets 
include genes previously shown to have important roles in Ewing sarcoma pathogenesis, but 
for which regulatory mechanisms have yet to be defined, such as CCND1 (Sanchez et al., 
2008), NKX2-2 (Smith et al., 2006), EZH2 (Riggi et al., 2008), and SOX2 (Riggi et al., 
2010). We also identified many additional targets of EWS-FLI1, such as OTX2 (Di et al., 
2005), MAFB (Vicente-Duenas et al., 2012), DEK (Riveiro-Falkenbach and Soengas, 2010) 
and API5 (Morris et al., 2006), which have yet to be implicated in Ewing sarcoma (Table 
S3, S4). Several of these activated targets have established roles as oncogenes in other 
cellular contexts. In contrast, genes directly repressed by EWS-FLI1 include the known 
tumor suppressors ERRFI1 (Duncan et al., 2010), CABLES1 (Arnason et al., 2013), IER3 
(Sebens Muerkoster et al., 2008), and TGFBI (Wang et al., 2012), as well as mesenchymal 
lineage factors, such as SNAI2 (Cobaleda et al., 2007), TRPS1 (Zhang et al., 2012), and 
CD73 (Chamberlain et al., 2007) (Table S3, S4).
We hypothesized that direct regulatory targets of EWS-FLI1 might represent attractive 
therapeutic targets in Ewing sarcoma and thus ranked target genes by combined changes in 
chromatin and expression (Fig. 5B). Several highly ranked genes in this set encode kinases. 
For example, PRKCB encodes protein kinase C-β, whose knock-down has previously been 
shown to induce apoptosis in Ewing cell lines (Surdez et al., 2012). Another top candidate is 
VRK1, a cell cycle dependent tyrosine kinase involved in G2-M transition (Valbuena et al., 
2011). VRK1 is proximal to an EWS-FLI1 dependent enhancer that is active in Ewing 
sarcoma cell lines and primary tumors and induced de novo by the fusion protein in MSCs 
(Fig. 5C). Chromatin conformation studies (3C) confirmed the long distance interaction 
between the EWS-FLI1-bound enhancer and the VRK1 promoter in both SKNMC and A673 
cells (Fig. 5D and E, respectively).
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VRK1 protein expression was confirmed in 15/15 primary Ewing sarcoma samples analyzed 
by immunohistochemistry, which revealed strong VRK1 signals in virtually all cells (Fig. 
6A and Fig. S5B). EWS-FLI1 knock-down markedly reduced VRK1 expression in the cell 
lines, while EWS-FLI1 induction was sufficient to up-regulate this kinase in MSCs (Fig. 6B 
and S5C). We directly tested the dependence of Ewing sarcoma cell lines on VRK1 by 
shRNA knock-down (Fig. S5D). The Ewing sarcoma cell lines displayed high sensitivity to 
suppression of this kinase, as indicated by a profound reduction in proliferation and a rapid 
onset of apoptosis (Fig. 6C, D and Fig. S5E and F). In contrast, VRK1 depletion in non-
Ewing sarcoma cell lines only moderately decreased proliferation and failed to trigger 
apoptosis, consistent with recent studies of its function in other tumor models (Kim et al., 
2013; Molitor and Traktman, 2013). Finally, injection of VRK1-depleted SKNMC cells 
immediately after lentiviral infection resulted in a marked decrease in tumor development in 
vivo (p-value < 10−5), confirming the critical role of this direct target in sustaining tumor 
cell proliferation and survival (Fig. 6E and F). Thus, de novo induction of enhancers 
through recognition of GGAA repeats enables EWS-FLI1 to activate genes essential for 
Ewing sarcoma proliferation and survival (Fig. 7).
Discussion
In summary, we have characterized the mechanisms by which a single oncogene reprograms 
the regulatory and transcriptional landscape of Ewing sarcoma. Through the coordinated 
analysis of chromatin states at EWS-FLI1 binding sites we find that the fusion protein is a 
major determinant of the regulatory activity of large set of enhancers shared by Ewing cell 
lines and primary tumors. Depending on the underlying DNA sequence of each binding site, 
the translocation can either repress its target by displacing more active wild type 
transcription factors or activate it by opening chromatin and recruiting chromatin modifying 
complexes to genomic regions previously devoid of regulatory function. These different 
modes of chromatin regulation have robust effects on enhancer activity and on the 
expression levels of their target genes, including oncogenes, tumor suppressors and 
mesenchymal markers with known or potentially novel roles in Ewing sarcoma.
Genome-wide chromatin profiling indicates that de novo conversion of non-functional 
GGAA repeats into active regulatory elements is the major mechanism of enhancer 
activation by EWS-FLI1. Binding of EWS-FLI1 to GGAA repeats has been previously 
reported, and sequences containing at least 4 GGAA repeats have been shown to favor the 
binding of EWS-FLI1 as homodimers (Gangwal et al., 2010). In addition GGAA repeats 
were the most significant motif in recent binding studies for EWS-ERG (Wei et al., 2010), 
the second most common chromosomal translocation in Ewing sarcoma, suggesting that 
similar regulatory mechanisms are shared by Ewing tumors with less frequent fusion 
partners. We now show that EWS-FLI1 operates as an oncogenic pioneer factor at GGAA 
repeat sites, mediating a transition from closed to open chromatin and establishing an active 
enhancer state. Induction of these sites is achieved despite notable lack of regulatory 
potential in mesenchymal stem cells, a putative cell-of-origin of this tumor, or in any other 
cell or tissue model represented in publically available accessibility datasets (Thurman et al., 
2012). EWS-FLI1 expression in mesenchymal stem cells can induce de novo chromatin 
opening and creation of active enhancers that closely resemble those present in Ewing cells 
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lines and primary tumors. Interestingly, while enhancers are often populated and driven by 
the binding of multiple collaborative transcription factors, our data suggest that the 
configuration of EWS-FLI1 as multimers at repeat sites is on its own sufficient to open 
chromatin and recruit methyltransferase and acetyltransferase activities to generate de novo 
active regulatory elements. Although it is possible that other DNA binding proteins may 
become involved in this process, the absence of pre-existing regulatory signals suggests that 
the fusion protein is the driving event for these striking changes in chromatin state.
The activity of EWS-FLI1 at GGAA repeats is also remarkable for the fact that these 
genomic locations are not conserved and do not appear to have regulatory functions in all 
other cellular contexts tested. The ENCODE DNAse I hypersensitivity data analyzed here 
includes profiles for endothelial and hematopoietic lines that express high levels of 
endogenous FLI1, yet there is no evidence of open chromatin at repeats bound by EWS-
FLI1. The large-scale conversion of GGAA repeats to critical tumor specific regulatory 
elements may thus be a property specific to the oncogenic fusion protein. These findings 
raise the intriguing possibility that other aberrant transcriptional mediators in cancer may 
also operate as pioneer factors to establish critical regulatory elements at DNA sites without 
normal regulatory activity or evolutionary conservation. It is worth noting that, while the 
lack of conservation of repeat sites suggests limitations for modeling EWS-FLI1 mediated 
events in other organisms, the ability of the fusion protein to act as a pioneer factor may 
result in the activation of different GGAA repeats near locations corresponding to EWS-
FLI1 binding sites in humans. It is thus possible that appropriately localized GGAA repeats 
may allow EWS-FLI1 to regulate some fraction of its target gene repertoire in other species 
(Tanaka et al., 2014). In contrast to activation, the direct repression of enhancers by EWS-
FLI1 occurs at non-repeat canonical ETS binding sites that display strong evolutionary 
conservation and regulatory activity in other cell types. In particular, DNAse I 
hypersensitivity and H3K27ac activation marks show that these sites often represent active 
enhancers in cells of mesenchymal origin. Thus, the known ability of EWS-FLI1 to block 
differentiation into mesenchymal lineages may be in large part mediated by the direct 
repression of enhancers that control normal developmental pathways. The finding that this 
mode of chromatin regulation by EWS-FLI1 is the result of competition and displacement of 
more active wild type ETS factors is particularly relevant for alterations in this large gene 
family and may also extend to other transcription factors with multiple roles in development 
and cancer.
Our data are consistent with a strong relationship between changes in chromatin states at 
enhancers and changes in transcriptional activity of proximal genes. In particular, among the 
genes affected we found oncogenes and tumor suppressors with known and potentially novel 
roles in Ewing sarcoma. Given the limitations of analytical methods for assigning enhancers 
to the nearest genes, we also sought to establish a direct physical interaction between 
activated enhancers sites and target promoters. Our chromatin conformation capture (3C) 
experiments for both the NKX2-2 and VRK1 loci demonstrate that GGAA repeats with active 
chromatin marks physically interact with target promoters by looping and thus appear to 
operate as typical enhancers to regulate gene expression. These findings suggest that the 
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genome-wide associations identified in our study may be mediated by similar mechanisms 
and that enhancer looping is a critical process in Ewing sarcoma pathogenesis.
The mechanisms identified in this study allow EWS-FLI1 to have a major impact on 
chromatin states and to establish the oncogenic regulatory landscape of Ewing sarcoma. 
Given the proposed origin of Ewing sarcoma from mesenchymal stem cells, the combined 
induction of oncogenic drivers and repression of mesenchymal differentiation pathways can 
serve powerful dual functions in oncogenesis. Characterization of chromatin states and 
remodeling events in additional tumor models may reveal new oncogenic addiction 
pathways and mechanisms that complement those gleaned from genetic and transcriptomic 
studies of cancer models. This is exemplified by the association between an aberrant distal 
regulatory element controlling VRK1 expression and the preferential dependency of Ewing 
sarcoma cells on this cell-cycle dependent kinase. Taken together, these observations 
suggest that rewiring of transcriptional regulatory mechanisms by superimposed epigenetic 
programs can drive functional tumor dependencies and underscore the potential of these 
analyses for understanding tumor biology and identifying novel therapeutic targets.
Experimental procedures
Cell Culture and primary tumors
Primary Ewing sarcoma specimens and mesenchymal stem cells were collected with 
approval by the Institutional Review Boards of Massachusetts General Hospital and Centre 
Hospitalier Universitaire Vaudois (CHUV, University of Lausanne). Samples were de-
identified prior to our analysis. Primary Ewing sarcoma tumors used for chromatin profiling 
were confirmed to express the EWS-FLI1 translocation by RT-PCR. Primary pediatric 
mesenchymal stem cells were cultured in IMDM containing 10% FCS and 10ng/ml PDGF-
BB (Peprotec), as previously described (Riggi et al., 2010). The Ewing sarcoma cell lines 
A673, SKNMC, CHP100, SKES1, EW7, as well as SaOS2, Hela and 293T cell lines were 
obtained from ATCC and grown in RPMI containing 10% FCS at 37°C with 5% CO 2. Cells 
were maintained between a density of 5 × 105 cells/ml and 2 × 106 cells/ml and split every 3 
– 4 days, following ATCC recommendations.
Real-time quantitative reverse transcriptase-PCR and Western Blot analysis
For gene expression assays, cDNA was obtained using a High Capacity RNA to cDNA kit 
(Applied Biosystems). 500 ng of template total RNA and random hexamers were used for 
each reaction. Real-time PCR amplification was performed using fast SYBR Green Master 
Mix (Life Technologies) and specific PCR primers in a 7500 Fast PCR instrument (Applied 
Biosystems). Relative quantification of each target, normalized to an endogenous control 
(GAPDH), was performed using the comparative Ct method (Applied Biosystems). Error 
bars indicate standard deviations. Western blotting was performed using standard protocols. 
Primary antibodies used for Western blotting were polyclonal rabbit anti-FLI1 (Santa Cruz, 
sc-356, 1:500 dilution), polyclonal rabbit anti-VRK1 (Santa Cruz, 1F6, 1:500 dilution) and 
monoclonal mouse anti-PARP (Santa Cruz, sc-8007, 1:500 dilution). Secondary antibody 
were goat anti-rabbit and goat anti-mouse IgG-HRP conjugated, (Bio-Rad, 1:20000 
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dilution). Membranes were developed using Western Lightning Plus-ECL, Enhanced 
Chemiluminescence Substrate (Perkin Elmer LLC) and visualized using photographic film.
EWS-FLI1 depletion and expression experiments
For knock-down experiments, the following lentiviral shRNAs were obtained from the 
RNAi Consortium in the pLKO.1 vector: FLI1 (TRCN0000005322), VRK1 
(TRCN0000197134, TRCN0000002133). The pLKO.1 shGFP control target sequence was 
GCAAGCTGACCCTGAAGTTCAT. The EWS-FLI1 type 1 expression plasmid has been 
previously described (Riggi et al, 2010). Lentiviruses were produced using standard 
protocols. Briefly, cDNA coding or shRNA plasmids were co-transfected with GAG/POL 
and VSV plasmids into 293T packaging cells using FugeneHD (Roche) to produce the virus. 
Viral supernatant was collected 72 hr after transfection and concentrated by 
ultracentrifugation using an SW41Ti rotor (Beckman Coulter) at 28,000 rpm for 120 min. 
RNA was extracted at the indicated time points using the Qiagen RNeasy kit, following 
manufacturer's instructions.
Proliferation and apoptosis assays
Viable cell lines were plated in 3 to 4 replicates in 24-well tissue culture plates. For 
proliferation assays, cells were titrated to allow log phase growth for a period of 5 days prior 
to readout (5000 cells per well). Cell proliferation and apoptosis were measured using the 
CellTiter-Glo Luminescent Cell viability assay and Caspase-Glo 3/7 Luminescent Assay, 
respectively (Promega), as described by the manufacturer. End-point luminescence was 
measured on SpectraMax M5 plate reader (Molecular Devices). The data displayed are 
representative of two similar experiments.
In vivo tumorigenic assay
For in vivo experiments 2 × 106 SKNMC cells were infected with shRNA hairpins targeting 
either GFP (control) or VRK1 gene sequences, harvested immediately after lentiviral 
infection and injected subcutaneously into 6 NOD/SCID mice for each condition. Mice were 
monitored daily for tumor development and sacrified 3 weeks later, when tumor weight and 
volume were assessed. Animal experiments were performed with approval of the 
Institutional Animal Care and Use Committee (IACUC) at Massachusetts General Hospital.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were carried out on A673, SKNMC and MSCs cultures of approximately 3 - 10 
× 106 cells per sample and per epitope, following the procedures previously described (Ku et 
al., 2008; Mikkelsen et al., 2007). Primary human tumors were processed as previously 
described (Aiden et al., 2010). Due to limiting amounts of material 3 out of 4 available 
frozen primary tumors were analyzed for each chromatin mark. In brief, chromatin from 
formaldehyde-fixed cells was fragmented to a size range of 200 - 700 bases with a Branson 
250 Sonifier. Solubilized chromatin was immunoprecipitated with antibodies against 
H3K4me3 (Millipore), H3K27me3 (Millipore), H3K27ac (Abcam, Active Motif), 
H3K4me1 (Abcam), FLI1 (Santa Cruz, sc-356), ELF1 (Santa Cruz, sc-631), GABPA (Santa 
Cruz, sc-22810), p300 (Santa Cruz, sc-585) or WDR5 (Bethyl, A302-429A). Antibody-
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chromatin complexes were pulled down with Protein G-Dynabeads (Life Technologies), 
washed and then eluted. After crosslink reversal, RNAse A and Proteinase K treatment, 
immunoprecipitated DNA was extracted with the Min-Elute PCR purification kit (Qiagen). 
ChIP DNA was quantified with Qubit. ChIP DNA samples were used to prepare sequencing 
libraries, and ChIP DNA and input controls were sequenced with the Hi-Seq Illumina 
Genome Analyzer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Direct enhancer activation or repression by a single aberrant transcription factor
• Chromatin remodeling at enhancer elements is dictated by underlying DNA 
sequence
• Divergent recruitment of chromatin remodeling complexes by EWS-FLI1
• De novo enhancers mediate tumor dependencies
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Significance
Cancer genome studies have identified many alterations in transcriptional regulators that 
have the potential to promote oncogenic gene expression programs. The impact of such 
changes is particularly evident in pediatric malignancies, where they may represent the 
sole event in tumor initiation. In our study, the integrated analysis of chromatin states in 
Ewing sarcoma reveals that EWS-FLI1 can either serve as a pioneer factor to generate 
enhancers de novo at repeat elements or repress conserved enhancers by competing with 
endogenous ETS factors. These data show how a single oncogenic transcription factor 
can directly orchestrate divergent patterns of chromatin remodeling in cancer and points 
to mechanisms that may be applicable to other tumors where transcriptional aberrations 
play a major role.
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Figure 1. EWS-FLI1 binds enhancer elements in Ewing sarcoma cell lines and primary tumors
(A) Heatmaps depict EWS-FLI1, H3K4me1 and H3K27ac signal intensities for 1604 EWS-
FLI1-bound distal regulatory elements. Rows: 10 kb regions, centered on EWS-FLI1 peaks, 
ranked by overall signal intensities of H3K4me1 and H3K27ac. (B) Heatmaps depict EWS-
FLI1 and H3K4me3 signals for 181 EWS-FLI1-peaks overlapping with transcriptional start 
sites (TSS). Rows: 10 kb regions, centered on EWS-FL1 peaks, ranked by overall signal 
intensities of H3K4me3. EWS-FLI1-binds to enhancers with variable levels of activity as 
demonstrated by the presence of the H3K4me1 mark and different levels of the H3K27ac 
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activation mark. In contrast EWS-FLI1 is primarily found at active promoters. (C) 
Composite plots showing average levels of H3K27me3 signals at EWS-FLI1 binding sites 
(left), compared to genome-wide signals at H3K27me3 peaks (right). (D) Examples of 
active distal regulatory elements near known EWS-FLI1 target genes in Ewing sarcoma cell 
lines (A673 and SKMNC) and a primary tumor. Tracks show EWS-FLI1, H3K27ac and 
H3K4me1 signals. EWS-FLI1 binding is highlighted in gray. See also Figure S1 and Table 
S1.
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Figure 2. EWS-FLI1 activates or represses enhancers depending on the underlying DNA 
sequence and differential recruitment of p300
(A) Heatmaps (left) and composite plots (middle) depicting H3K27ac and p300 signal 
intensity changes across EWS-FLI1 peaks after EWS-FLI1 knock-down in SKNMC cells at 
indicated time points. Binding sites are classified as repressed if EWS-FLI1 depletion results 
in increased H3K27ac and p300 signals (top, 330 sites, 1.5 fold increase in H3K27ac), or 
activated if depletion results in decreases in H3K27ac and p300 (bottom, 1011 sites, 1.5 fold 
decrease in H3K27ac). Right: de novo motif analysis of repressed peaks shows strong 
enrichment for the canonical ETS factor family motifs (p = 1e−129, top); activated peaks 
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show enrichment for consecutive GGAA repeat elements (p = 1e−878, bottom). (B) Signal 
tracks for representative repressed binding sites (ENC1 and RAB3GAP2) in SKNMC cells. 
EWS-FLI1, H3K27ac and p300 signals for shGFP or shFLI1 infected cells are shown. The 
genomic sequence for the EWS-FLI1 binding site near ENC1 is provided (single GGAA). 
(C) Signal tracks for representative activated binding sites (NKX2-2 and NPY1R) as in (B). 
The genomic sequence for the EWS-FLI1 binding site near NKX2-2 is provided (GGAA 
repeats). Areas of EWS-FLI1 binding are highlighted in gray. These data suggest that 
repression and activation of EWS-FLI1 bound sites rely on two distinct chromatin 
remodeling mechanisms, dictated by the underlying genomic sequence and the differential 
recruitment of p300. See also Figure S2.
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Figure 3. EWS-FLI1 binding leads to opening of chromatin and recruitment of chromatin 
remodeling complexes to induce de novo active enhancers at DNA repeats lacking regulatory 
functions in other contexts
(A) Boxplots for DNAseI signals at activated (top) or repressed (bottom) EWS-FLI1 binding 
sites across 112 cell lines profiled by ENCODE. SKNMC cells are shown in red. (B) 
Conservation scores (PhastCons) in 100 vertebrate species for 2 kb intervals centered on 
activated or repressed EWS-FLI1 binding sites. (C) Left: Comparison of H3K27ac changes 
at EWS-FLI1 binding sites after introduction of EWS-FLI1 in MSCs or after EWS-FLI1 
depletion in SKNMC cells. Activated EWS-FLI1 binding sites are boxed with a dashed line. 
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Right: Boxplots of H3K27ac (top) and H3K4me1 (bottom) signal intensities at 1011 EWS-
FLI1 activated sites after introduction of EWS-FLI1 in MSCs (blue) compared to an empty 
vector control (black). Signals for both enhancer marks are significantly induced following 
EWS-FLI1 expression. (D) Composite plots of WDR5 and H3K4me1 signals at activated 
EWS-FLI1 binding sites in MSCs expressing EWS-FLI1 or infected with an empty vector. 
Signals in SKMNC cells are shown on the right panel for comparison. (E) Heatmaps depict 
signals for ATAC-seq, WDR5, H3K4me1 and H3K27ac at activated binding sites as in C, 
either from empty vector infected or EWS-FLI1-expressing MSCs. (rows: ATAC-seq 2 kb 
region, WDR5-H3K4me1-H3K27ac 10 kb regions, centered on EWS-FLI1 peaks). (F) 
Signal tracks for FLI1, H3K4me1, H3K27ac, WDR5 and ATAC-seq at the NKX2-2 locus in 
SKNMC cells, and MSCs expressing EWS-FLI1 (E-F) or empty vector control (Co). EWS-
FLI1 expression in MSCs leads to nucleosomal rearrangement, WDR5 recruitment, and de 
novo deposition of both enhancer marks H3K4me1 and H3K27ac, recapitulating the open 
active chromatin architecture of SKNMC cells. (G-H) 3C-qPCR analysis of long-distance 
interactions between the NKX2-2 promoter and the corresponding EWS-FLI1-bound distal 
regulatory element in SKNMC (G) and primary mesenchymal stem cells (H). A strong 
interaction is present between the distal regulatory element and the promoter of NKX2-2 in 
SKNMC cells. No significant interaction is observed in MSCs until introduction of EWS-
FLI1 leads to DNA looping (H) to produce a conformation similar to SKNMC cells. The 
human NKX2-2 locus is depicted above each graph. The x-axes represent distances (kb) 
from the NKX2-2 promoter. A red arrow denotes the HindIII fragment serving as anchor, 
black and blue arrows denote the analyzed HindIII fragments. P: promoter; E: enhancer. 
Error bars represent standard deviations. See also Figure S3.
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Figure 4. EWS-FLI1 represses conserved distal regulatory elements by displacing endogenous 
wild type ETS factors
(A) Boxplots of H3K27ac signal intensities at distal elements corresponding to EWS-FLI1 
peaks (repressed sites = blue, activated sites = black) in H1 embryonic stem cells, H1-
derived NPCs (neural progenitor cells), H1-derived MSCs, bone marrow-derived MSCs, 
osteoblasts, skeletal muscle myoblasts (HSMM) and dermal fibroblasts (NHDF). Repressed 
EWS-FLI1 bound distal elements in Ewing sarcoma are active in normal mesenchymal cell 
types but not in H1 ES cells or H1-derived NPCs. (B) Composite plots show EWS-FLI1 
(left) and ELF1 (right) signal intensities for 330 repressed EWS-FLI1 binding sites upon 
EWS-FLI1 depletion in SKNMC cells. (C) Heatmaps depict signals for EWS-FLI1, ELF1 
and p300 at the same repressed sites (rows: 2 kb regions centered on EWS-FL1 peaks). 
ELF1 binding is observed at many of these sites upon EWS-FLI1 depletion. (D) Signal 
tracks for EWS-FLI1, H3K27ac, p300 and ELF1 at the ENC1 locus in SKMNC cells. After 
EWS-FLI1 depletion ELF1 binding leads to p300 recruitment and enhancer activation. 
Areas of EWS-FLI1 binding are highlighted in gray. See also Figure S4s.
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Figure 5. Combined analysis of epigenetic states, transcriptional changes and chromatin 
conformation identifies the tyrosine kinase VRK1 as a direct EWS-FLI1 target gene in Ewing 
sarcoma
(A) Box-plots show Z-scores for gene expression changes vs Z-scores for H3K27ac 
chromatin changes after EWS-FLI1 knock-down in SKNMC and A673 cells (48 hr). Z-
scores provide a measure of effect size and consistency between cell lines. The nearest 
expressed genes in SKNMC and A673 cells were assigned to each binding site. (B) 
Heatmaps depict fold changes in H3K27ac and gene expression in A673 and SKNMC 
Ewing cells after EWS-FLI1 knock-down (48 hr). Genes were ranked by the combined 
significance of H3K27ac and gene expression changes (average z-score). The top 100 
activated or repressed enhancer binding sites and genes are shown in the heatmap and the 
top 10 annotated genes are listed on the right. (C) Track signals for FLI1, H3K27ac and 
RNA-seq in SKNMC after EWS-FLI1 depletion (96 hr) identify an active regulatory 
element distal to VRK1 (top). The same enhancer element is present in primary Ewing 
tumors (middle), and is generated de novo by EWS-FLI1 expression in MSCs (bottom). P: 
promoter; E: enhancer. (D-E) 3C-qPCR analysis of long-distance interactions between the 
VRK1 promoter and the corresponding EWS-FLI1-bound distal regulatory element in 
SKNMC (D) and A673 cells (E). The human VRK1 locus is depicted below each graph. The 
x-axes represent distances (kb) from the VRK1 promoter. Red arrow denotes the HindIII 
fragment serving as anchor, black and blue arrows denote the analyzed HindIII fragments. P: 
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promoter; E: enhancer. Error bars represent standard deviations. See also Figure S5, Table 
S3 and S4.
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Figure 6. VRK1 is highly expressed in primary Ewing sarcoma and its depletion strongly 
reduces tumor proliferation and survival in vitro and in vivo
(A) VRK1 is expressed in the majority of Ewing sarcoma cells, as assessed by 
immunohistochemistry of primary tumors (magnification: 400x, scale bar: 50 uM). (B) Left: 
VRK1 mRNA expression in A673 and SKNMC cells after EWS-FLI1 depletion (shFLI1) 
compared to control (shGFP). Right: VRK1 mRNA expression in MSCs after introduction 
of EWS-FLI1 (pLIV EWS-FLI1) compared to control cells (pLIV empty). Error bars 
represent standard deviations. (C) Proliferation rates and relative apoptosis (D) of a panel of 
tumor cell lines after VRK1 knock-down compared to control (shGFP). Error bars represent 
the standard deviation of three replicates. Ewing sarcoma cells display selective high 
sensitivity toward VRK1 depletion, compared to Saos-2 (osteosarcoma) and HeLa cells. (E-
F) VRK1 depletion markedly reduces tumor growth in immunocompromised mice, as 
assessed by tumor weight (E) and volume (F) 3 weeks after subcutaneous injection of 
control or VRK1-depleted SKNMC cells. Error bars represent standard deviations.
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Figure 7. Mechanisms of enhancer remodeling driven by EWS-FLI1
Schematic illustrating the two distinct chromatin remodeling mechanisms underlying EWS-
FLI1 divergent transcriptional activity: enhancer induction and activation (upper panel) with 
recruitment of WDR5 and p300 at GGAA repeats, and enhancer repression (lower panel) 
with displacement of endogenous ETS transcription factors and p300 at single GGAA 
canonical ETS motifs.
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